Untreated APP/PS1 mice weighed significantly more at 5–6 months of age than FK506-treated wild-type, treated APP/PS1, or control C57/Bl6 mice (Fig. 1B), suggesting FK506 prevented weight gain and obesity [36]. Here, APP is linked to obesity due to melanocortin 4 receptor deficiency.